Certara’s (CERT) Market Perform Rating Reiterated at William Blair

William Blair reaffirmed their market perform rating on shares of Certara (NASDAQ:CERT) in a research report released on Thursday,RTT News reports.

A number of other equities research analysts also recently issued reports on CERT. Barclays reduced their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Stephens reaffirmed an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research report on Thursday. TD Cowen assumed coverage on shares of Certara in a research report on Thursday. They set a “buy” rating and a $16.00 target price for the company. Finally, Robert W. Baird reduced their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.83.

Certara Trading Down 3.4 %

Shares of CERT stock opened at $11.98 on Thursday. Certara has a 52-week low of $9.41 and a 52-week high of $19.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company has a 50-day simple moving average of $12.45 and a two-hundred day simple moving average of $11.63. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -59.90, a PEG ratio of 9.29 and a beta of 1.57.

Institutional Trading of Certara

Institutional investors have recently modified their holdings of the business. Brown Brothers Harriman & Co. purchased a new stake in shares of Certara during the 3rd quarter valued at approximately $27,292,000. Kopion Asset Management LLC lifted its stake in shares of Certara by 46.0% during the 4th quarter. Kopion Asset Management LLC now owns 555,643 shares of the company’s stock valued at $5,918,000 after buying an additional 175,005 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Certara by 40.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after buying an additional 1,128,006 shares in the last quarter. Vontobel Holding Ltd. purchased a new stake in shares of Certara during the 4th quarter valued at approximately $1,295,000. Finally, Barclays PLC lifted its stake in shares of Certara by 198.3% during the 3rd quarter. Barclays PLC now owns 70,525 shares of the company’s stock valued at $825,000 after buying an additional 46,880 shares in the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.